Search clinical trials for: CHF6563

Total 9 results

Chiesi Farmaceutici S.p.A.

Completed

Investigate the Safety, Tolerability and Pharmacokinetics of CHF6523 in Healthy and in COPD Subjects (CHF6523)

COPD

United Kingdom
Chiesi Farmaceutici S.p.A.

Recruiting

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Inhaled CHF6333 After Single Doses in Healthy Volunteers and After Single and Repeated Doses in Subjects With Bronchiectasis

Bronchiectasis

United Kingdom
Chiesi Farmaceutici S.p.A.

Terminated

CHF6563 in Babies With Neonatal Opioid Withdrawal Syndrome (NOWSHINE)

Neonatal Opioid Withdrawal Syndrome

United States
Chiesi Farmaceutici S.p.A.

Completed

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366

Chronic Obstructive Pulmonary Disease | Asthma

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects (CHF6333 FIH)

Cystic Fibrosis | Non-Cystic Fibrosis Bronchiectasis

Belgium
Chiesi Farmaceutici S.p.A.
Comac Medical

Completed

CHF6467 SAD and MAD in Patients With Diabetic Foot Ulcer

Diabetic Neuropathic Foot Ulcers

Bulgaria
Benedetto Falsini

Recruiting

Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG) (NGF-OPG)

Optic Pathway Glioma

Italy
Chiesi Farmaceutici S.p.A.

Completed

A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)

Respiratory Distress Syndrome, Newborn

United States
Chiesi Farmaceutici S.p.A.

Completed

First In Human Study on Synthetic Surfactant CHF 5633 in Respiratory Distress Syndrome

Respiratory Distress Syndrome in Premature Infants

United Kingdom

3

Subscribe